Syncromune, Inc. Announces FDA Clearance of IND Application

Syncromune, Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer

Syncromune, Inc. Announces FDA Clearance of IND Application for SYNC-T SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

United States , Michael Tattory , Danielle Hobbs , Eamonn Hobbs , Drug Administration , Corporate Communications , Exchange Commission , Syncromune Inc , Lifesci Communications , None Of Syncromune Inc , Metastatic Castrate Resistant Prostate , Charles Link , Fort Lauderdale , Securities Act ,